CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,776 | -31.3% | 1,638,858 | 0.0% | 1.53% | -5.0% |
| Q2 2023 | $52,099 | +11.6% | 1,638,858 | -14.4% | 1.62% | -41.8% |
| Q1 2023 | $46,694 | -22.1% | 1,914,466 | +0.8% | 2.78% | -17.0% |
| Q4 2022 | $59,926 | -99.9% | 1,900,000 | -5.0% | 3.34% | +38.7% |
| Q3 2022 | $56,520,000 | +42.5% | 2,000,000 | +33.3% | 2.41% | +13.9% |
| Q2 2022 | $39,660,000 | -24.5% | 1,500,000 | 0.0% | 2.12% | -3.7% |
| Q1 2022 | $52,515,000 | +8.0% | 1,500,000 | 0.0% | 2.20% | +66.6% |
| Q4 2021 | $48,630,000 | -8.4% | 1,500,000 | -16.7% | 1.32% | +11.1% |
| Q3 2021 | $53,100,000 | +3.6% | 1,800,000 | -10.0% | 1.19% | +14.2% |
| Q2 2021 | $51,240,000 | +49.3% | 2,000,000 | -20.0% | 1.04% | +71.6% |
| Q1 2021 | $34,325,000 | -9.3% | 2,500,000 | +9.5% | 0.61% | -25.4% |
| Q4 2020 | $37,837,000 | – | 2,282,100 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |